Phase 2 study of talabostat and cisplatin in stage IV melanoma.

被引：0
|
作者：
Uprichard, MJ
O'Day, SJ
Pavlick, AC
Richards, DA
Frenette, G
Stephenson, J
Anthony, S
Pacciucci, PA
Vrhovac, V
Cunningham, C
机构：
[1] Point Therapeut, Boston, MA USA
[2] Inst Canc Res, Med Grp, Los Angeles, CA USA
[3] NYU, Kaplan Canc Ctr, New York, NY 10016 USA
[4] Tyler Canc Ctr, Tyler, TX USA
[5] Carolinas Med Ctr, Charlotte, NC USA
[6] Canc Ctr Carolinas, Greenville, SC USA
[7] Canc Ctr NW, Spokane, WA USA
[8] Mary Crowley Med Res Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：725S / 725S
页数：1
相关论文
共 50 条
  • [21] Treatment of patients with inoperable stage III or stage IV melanoma. Societe francaise de dermatologie
    Guillot, B.
    Charles, J.
    Jeudy, G.
    Cupissol, D.
    Dupuy, A.
    Dutriaux, C.
    Gangloff, D.
    Magne, N.
    Mirabe, X.
    M'Sadek, A.
    Pracht, M.
    Sichel, C.
    Do Outeiro, G.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (6-7): : 413 - 422
  • [22] Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma.
    Letsch, A.
    Scheibenbogen, C.
    Fluck, M.
    Asemissen, A.
    Nagorsen, D.
    Thiel, E.
    Keilholz, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 117S - 117S
  • [23] Cisplatin (CDDP), dacarbazine (DTIC), interferon (IFN) and amifostine (AMI) in advanced melanoma.: A phase I study
    Daponte, A
    Rivellini, F
    Gravina, A
    Ascierto, PA
    D'Aniello, R
    Mozzillo, N
    Caracò, C
    Comella, P
    Castello, G
    Comella, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S373 - S373
  • [24] A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.
    Albertini, Mark R.
    Ranheim, Erik
    Hank, Jacquelyn A.
    Zuleger, Cindy
    McFarland, Thomas
    Collins, Jennifer
    Clements, Erin
    Weber, Sharon M.
    Weigel, Tracey
    Neuman, Heather B.
    Hartig, Gregory K.
    Mahvi, David
    Henry, MaryBeth
    Gan, Jacek
    Yang, Richard
    Kim, KyungMann
    Gillies, Stephen
    Sondel, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Adjuvant chemotherapy versus biochemotherapy for stage II malignant melanoma. A phase II/III study
    Andreadis, Charalampos
    Boutis, Anastasios
    Michou, Dimitra
    Oikonomou, Spiros
    Vachtsevanos, Kostas
    Mouratidou, Despina
    ANNALS OF ONCOLOGY, 2004, 15 : 202 - 203
  • [26] A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma.
    Fruehauf, J. P.
    Eroglu, Z.
    Kong, K. M.
    Jakowatz, J. G.
    Akerley, W. L.
    Samlowski, W. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma.
    Kudchadkar, Ragini Reiney
    Gibney, Geoffrey Thomas
    Dorman, Denise
    Merek, Stephanie
    Ramadan, Howida
    Chen, Ann
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.
    Chan, Pui Ying
    Phillips, Melissa Mary
    Khadeir, Ramsay
    Ellis, Stephen
    Thomson, Jim
    Johnston, Amanda
    Feng, Xiaoxing
    Wu, Bor-Wen
    Bomalaski, John S.
    Sheaff, Michael
    Szlosarek, Peter Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] A 2-stage, randomized, blinded phase 2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma.
    Powderly, J
    Khan, K
    Urba, W
    Richards, JM
    Hurwitz, C
    McLeod, M
    Dahl, TA
    Sherman, MS
    O'Day, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9122S - 9123S
  • [30] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
    Atkins, Michael B.
    Reiney, Ragini
    Sznol, Kudchadkar Mario
    McDermott, David F.
    Lotem, Michal
    Schachter, Jacob
    Wolchok, Jedd D.
    Urba, Walter John
    Kuzel, Timothy
    Schuchter, Lynn Mara
    Slingluff, Craig L.
    Ernstoff, Marc S.
    Fay, Joseph W.
    Friedlander, Philip Adam
    Gajewski, Thomas
    Zarour, Hassane M.
    Rotem-Yehudar, Rinat
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345